Heptares Therapeutics
James Kean started their work experience as a Research Scientist at Heptares in June 2009. James worked there until December 2012 before being promoted to the role of Senior Scientist I. In December 2015, they were promoted again to the position of Senior Scientist II. During their time at Heptares, they conducted research and worked on various projects related to membrane protein structure and function. In August 2017, James joined Heptares Therapeutics Zürich AG as a Senior Scientist II, where they continued their work until April 2019. James then moved on to Sosei Heptares, where they held the position of Senior Scientist II until December 2019. Finally, in December 2019, James became a Principal Scientist at Sosei Heptares, where they are currently employed. Prior to their industry experience, James was a PhD student at the University of Manchester from 2005 to 2009, working on the membrane protein structure initiative. James developed a thermofluor-based assay during their research to determine the thermal stability of membrane proteins.
James Kean obtained a BSc in Biochemistry from The University of Sheffield, where they studied from 2002 to 2005. Following this, they pursued a PhD in Protein Biochemistry at The University of Manchester, completing their studies from 2005 to 2009.
This person is not in any teams
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.